Melatonin and neuroblastoma: a novel therapeutic approach

Area of Science:

• Pediatric Oncology
• Endocrinology
• Cancer Biology

Background:

• Neuroblastoma remains a significant cause of childhood mortality despite treatment advancements.
• There is a critical need for novel complementary and alternative therapies to improve outcomes.
• Melatonin, a pineal gland hormone, possesses known multifunctional and anticancer properties.

Purpose of the Study:

• To review and synthesize current scientific evidence on the anti-neuroblastoma effects of melatonin.
• To explore the specific cellular pathways through which melatonin exerts its effects against neuroblastoma.

Main Methods:

• Comprehensive literature review of preclinical and clinical studies.
• Analysis of research investigating melatonin's impact on neuroblastoma cell lines and animal models.
• Examination of studies detailing melatonin's molecular mechanisms of action.

Main Results:

• Evidence suggests melatonin inhibits neuroblastoma cell proliferation, induces apoptosis, and reduces metastasis.
• Melatonin impacts various cellular pathways, including cell cycle regulation, oxidative stress, and signaling cascades.
• Studies indicate a potential synergistic effect when melatonin is combined with conventional therapies.

Conclusions:

• Melatonin demonstrates significant potential as an alternative or complementary therapeutic agent for neuroblastoma.
• Further research into melatonin's specific mechanisms and clinical efficacy is warranted.
• Targeting cellular pathways with melatonin may offer a novel strategy to combat pediatric neuroblastoma.